tirzepatide trials on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial Read now: The SURPASS-EARLY trial

Activation of gastrointestinal ileal brake response with dietary slowly digestible carbohydrates, with no observed effect on subjective appetite, in an acute randomized, double-blind, crossover trial

The American Association for the Study of Liver Diseases (AASLD) acknowledges the potential role of GLP-1 receptor agonists in managing MASLD, particularly in patients with concurrent type 2 diabetes or obesity

If youre trying to understand how it fits into the current landscape of weight loss medications, and how it stacks up against GLP-1 options like semaglutide and tirzepatide, heres a clear-eyed look at what the evidence actually shows

This will be different for everyone and will depend on how much progress you make or how much weight you have to lose

Semaglutide added to basal insulin in type 2 diabetes: SUSTAIN 5